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ha cystic fibrosis (CF), the course of the disease varies between homozygous 
canciers, and this is thought o reflect the contribution of genetic polymorpbisms 
which can exacerbate he associated pulmonary inflammation. We have previously 
shown that neutropbils of CF patients have higher myeloperoxidase (MPO) enzyme 
activity. Airr~" To test whether a functional MPO promoter polymorpbism ilffluenced 
their clinical outcome. The ~,63G/A polymotpbism is linked to differences in MPO 
expression levels, with the GG genotype associated with increased MPO. The 
clinical status of 88 patients with CF was evaluated. Results: ha the group of non 
infected CF patients, there is significantly lower FEV or FVC ha CF patients with 
GG than GA genotype. There w re more lesions seen on chest radiography in GG
than in GA and Shwachman scores were decreased in the group of GG genotype as 
compared to GA. In contrast, ha the group of infected CF patients, there was no 
significant difference in clinical parameters between GG and GA genotypes. 
Conclusion: MPO genotype significantly influences the severity of pulmonary 
disease in early stages, prior to development of chronic lung infections, with GG 
genotype being associated with more severe CF disease. These findings indicate 
that he level ofMPO gene expression hffluences the pathogenesis of CF, reflecting 
cellular damage by MPO generated oxidants. 
Supports: "ABCF protein association", Vaincre la Mucoviscidose" and National 
Institutes of Health iGrant WR: RO1 AG17879). 
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AssociaSon of the group specific component (GC) gene 
polymorphisms with severe cystic fibrosis lung disease 
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Oy st ic fibrosis (CF), the most common genetic disease in the white population. The 
major cause of morbidity and mortality for individuals with CF is pulmonary 
disease due to cbr onic infection and damaging host hfflammat ory response. Group 
specific component (GC) is known to bind with vitamin D, extracellular actin and 
endotoxin. CG enhances the neutrophil chemotactic activity of complement 
component 5a (C5 a) peptide and C5a des Arg produced uring the activation of the 
complement cascade. In addition, CG can be converted into a macrophage 
activating factor. GC may therefore have important ilRluences on the intensity of the 
ilRlammatory reactions ha the lung. 
Method: The study group consisted of 62 Tatars children with severe CF recruited 
from Republican Children's Hospital (Ufa city, Russia). ha control, the DNA 
samples from 227 unrelated healthy etlmically, age and sex matched individuals 
were used. The GC gene polymorpbisms (Glu416Asp, Tbr420Lys) were typed 
using PCR RLFR 
Results: Genotype and allele distribution of the Tbr420Lys polymorpbism was 
similar among the CF and healthy subjects. Patients with CF showed elevated 
frequency of the 416 Asp/Asp genotype of GC gene 41.94% compared to control 
25,57% (Z2 5.49 P~).02; OR 2.1 CI95% 1.11 3.94). The association between GC 
gene haplotypes and the incidence of severe CF in children was also analyzed. 
Frequency of the IF/1F haplotype was significantly higher ha patients with CF 
29.03% compared to conlrol 11.52% (Z2 10.03 P~).CO2; OR 3.14 CI95% 1.49 
6.6). 
Conclusions: It is suggested that the IF/1F haplotype of the GC play a substantial 
part in predisposition to severe airway inflammation atchildren with cystic fibrosis. 
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Incidence of the IL-8 251 polymorphism and association with lung 
funcSon in the Northern Ireland CF population 
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haterleukin 8 (IL 8) is a pro hfflammatory cytokine fundamental in promoting 
neutropbil dominated ilRlammation ha CE The IL 8 251 polymolpbism is found ha 
the promoter region of the IL 8 gene, the A allele is associated with increased IL 8 
production. 
Aims: Frequency of the IL 8 polymorphism was analysed to investigate potential 
CF related association in the Northem Ireland (NI) population. The relationship 
between high and low producing alleles of IL  8 with lung function (%FEVI) was 
investigated. 
Methods: 1CO conlrol samples (59% female, 41% male, 1945y) were chosen at 
random from the NI population. 101 CF DNA samples (50.5% female and 49.5% 
male, 15 50y) from the NI population were studied. Analysis of the IL 8 
polymorphism was performed using PCR followed by sequence specific 
oligonucleotide probes. 
Results: Genotyping of the IL 8 251 polymorpbism revealed that 23 (22.8%) of CF 
individuals were AA (high producers), 49 (48.5%) were AT (intermediate 
producers) and 29 (28.7%) were "IT (low producers). In the conlrol population 25 
(25%) were AA, 45 (45%) were AT and 30 (30%) were "IT. There was no significant 
variationbetweenthe wogroups for the IL 8 (P 0.926) polymorpbism. CFpatients 
homozygous for AA (n 23) and those homozygous for TT (n~49) had significantly 
lower % FEV 1 than those who were heter ozygous AT for the IL 8 allele (AT, 74.9 + 
3.1%, AA, 63.6 + 4.9%, P 0.04, "IT 55.7 +4.3%, P~).CO1). 
Conclusions: These results suggest that patients with CF who are homozygous for 
the high producing A or low producing T alleles are at a disadvantage to those who 
are heterozygous a reflected ha lower %FEV v 
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Introduction: Cystic fibrosis is a genetic disorder that during its course presents 
mainly pulmonary and pancreatic manifestations. The correlation between genotype 
and phenotype is not clear in cystic fibrosis. The severity of disease is not related to 
the CFFR genotype. Alpha 1 antitl3,psin inhibits the proteases that release 
ilRlammatory reactions of the plasma. Its most important inhibitory role is it action 
against leukccytic elastase. As the deficiency of alpha 1 antitrypsin has relevant 
pulmonary manifestations and is common in the area, we believe that it may be able 
to modulate pulmonary manifestations in cystic fibrosis patients. Aims: The 
objective of this study was to ascertain the distribution of A1AT genotypes and 
severity of pulmonary disease in patients with cystic fibrosis. Methods: We studied 
70 patients; nine (12.8%) were heterozygotes for S or Z allele or compound 
heterozygotes (SZ). Results: No significant differences were found in clinical 
severity of CF between genotypes of A1AT. No significant differences were found 
when the patients were separated by the presence or absence of AF508 mutation. 
Conclusions: We concluded that the common MS, SS, MZ genotypes of A1AT 
deficiency that cause mild to moderate protein deficiency are not associated with 
severity of disease deterioration i Brazilian patients with cystic fibrosis. This is the 
first study about the relation between Alpha 1 antitrypsin deficiency and Oystic 
fibrosis made ha Brazil. 
